EN DE
STOCK COMPARISON

Zhangzhou Pientzehuang Pharmaceutical Co vs Eli Lilly and: Fair Value & Quality

Both stocks run through our valuation models. Here is how Zhangzhou Pientzehuang Pharmaceutical Co (600436) and Eli Lilly and (LLY) compare, as of Sep 22, 2026.

As of Sep 22, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Zhangzhou Pientzehuang Pharmaceutical Co trades at ¥118 versus a fair value of ¥58.00 (-51%), while Eli Lilly and trades at $1,153 versus $779 (-32%).
Zhangzhou Pientzehuang Pharmaceutical Co
600436.SHG · CNY · Health Care
-51%
upside to fair value
overvalued
Price¥118
Fair Value¥58.00
Quality56/100
Eli Lilly and
LLY · USD · Health Care
-32%
upside to fair value
overvalued
Price$1,153
Fair Value$779
Quality69/100
Get comparisons like this free by email every month: the most undervalued quality stocks.

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Zhangzhou Pientzehuang Pharmaceutical CoEli Lilly and
Valuation
43.5×P/E (TTM)42.2×
9.61×P/S (TTM)14.67×
5.68×P/B39.94×
41.4×EV/EBITDA30.2×
—PEG1.54×
−51.0%Fair value upside−32.4%
2.4%Dividend yield0.5%
¥2.97Dividend per share$6.23
Profitability
31%Operating margin49%
0.87×EBIT margin trend (5Y)1.42×
12%Return on equity107%
6%Return on assets21%
Growth
-13%Revenue growth (YoY)56%
1.2%Avg. growth/yr (3Y)31.7%
6.7%Avg. growth/yr (5Y)21.6%
+7.6%Value creation/yr+26.5%
Balance & size
70.9×Interest coverage (EBIT/interest)37.3×
0.00×Debt / equity1.54×
$12BMarket cap$1.1T
expensiveGrowth qualitymixed

Eli Lilly and leads: 5 to 10 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Zhangzhou Pientzehuang Pharmaceutical Coof which business quality 53 · market factors 36 Eli Lilly andof which business quality 65 · market factors 79
ProfitabilityMargins and returns on capital today
59
85
Quality GrowthAre margins and returns improving?
21
86
CashflowEarnings quality: real cash, not paper profit
6
51
Fin. StrengthBalance sheet, leverage, solvency risk
84
53
InvestmentDisciplined investing over empire-building
72
15
Low VolatilityCalm price path (market factor)
85
77
MomentumPrice trend over the last 3–12 months (market factor)
21
75
52W MomentumDistance to the 52-week high (market factor)
6
88
Net IssuanceShare count: buybacks or dilution?
82
93

What the models say

How far the median fair value (base case) per model family sits from the current price, in percent. The amount in the currency of the trading venue is shown underneath.

above the price, more than 15% above close to the price, 85% to 115% of the price below the price, more than 15% below

Model familyZhangzhou Pientzehuang Pharmaceutical CoPrice ¥118Eli Lilly andPrice $1,153
DCF Models-19%below the price¥96.16-71%below the price$334
Earnings-Based-51%below the price¥58.00-79%below the price$239
Dividend Discount-51%below the price¥57.39-90%below the price$115
Multiples-50%below the price¥58.91-69%below the price$358
Asset-Based-86%below the price¥16.15-98%below the price$19.94
Growth DCFn/a-84%below the price$187
Economic Profit-68%below the price¥37.79-70%below the price$347
Growth Earnings-27%below the price¥86.93-68%below the price$375
Minimum-86%below the price¥16.15-98%below the price$19.94
Maximum-19%below the price¥96.16-68%below the price$375
Median-51%below the price¥58.00-75%below the price$287
Geometric mean-56%below the price¥51.80-84%below the price$189

Minimum, maximum, median and geometric mean refer to the family values in this table. Geometric because deviations are ratios: half the price and twice the price average to 100%, not 125%.

Zhangzhou Pientzehuang Pharmaceutical Co: 16 of 17 models see the stock below the current price.

Eli Lilly and: 26 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear scenario to the optimistic bull scenario. The white tick is the current price (value above it), the green tick the fair value (value below it): if the price sits left of the fair value, there is room to rise.

Zhangzhou Pientzehuang Pharmaceutical Co
Price ¥118
Fair Value ¥58.00
Bear ¥29.80Bull ¥75.40
Eli Lilly and
Price $1,153
Fair Value $779
Bear $391Bull $1,165

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Zhangzhou Pientzehuang Pharmaceutical Co · Health Care

Quality score56 · above median
Fair value upside-51% · below median

Eli Lilly and · Health Care

Quality score69 · Top 25%
Fair value upside-32% · below median

Bottom line

As of Sep 22, 2026, Fair Value Calculator sees Eli Lilly and as the less overvalued of the two: Zhangzhou Pientzehuang Pharmaceutical Co trades at ¥118 versus a fair value of ¥58.00 (-51%), while Eli Lilly and trades at $1,153 versus $779 (-32%).

Eli Lilly and has the higher quality score (69/100).

See the full analysis →
Zhangzhou Pientzehuang Pharmaceutical Co · Eli Lilly and

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Zhangzhou Pientzehuang Pharmaceutical Co

Microsoft vs NvidiaApple vs MicrosoftMicrosoft vs Taiwan Semiconductor ManufacturingCisco Systems vs Nvidia

Related to Eli Lilly and

Alphabet Inc Class C vs Meta PlatformsApple vs Cisco SystemsBroadcom vs MicrosoftMicrosoft vs Micron Technology
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 26 models. Values change with price and fundamentals; the date shown above applies.